Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Table 3 Results of incremental economic analysis

Treatment	Mean Cost	Mean QALYs	Inc. Cost	Inc. QALY	ICER	ICER v Conventional
At 10 years
Conventional management strategy	£15,587	3.8	-	-	-	-
Adalimumab	£39,070	4.5	£23,484	0.7	Ext Dom’d	£31,830
Golimumab	£45,990	4.7	£6,920	0.2	Dom’d	£33,178
Etanercept	£44,701	4.8	£29,115	1.0	£28,917	£28,917
Infliximab	£56,009	4.9	£11,308	0.1	£86,499	£35,534
At 40 years
Conventional management strategy	£43,391	5.2	-	-	-	-
Adalimumab	£69,332	6.7	£25,941	1.5	Ext Dom’d	£17,222
Golimumab	£76,976	7.1	£7,629	0.4	Dom’d	£17,435
Etanercept	£75,563	7.2	£32,171	2.0	£16,426^a	£16,426
Infliximab	£88,362	7.4	£12,799	0.2	£62,527^b	£20,789

Dom’d, dominated (Treatment costs more and is less effective than the other intervention); Ext Dom’d, extendedly dominated (ICER is greater than that of the more effective intervention); ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years.
^aCompared with the next most effective strategy (excluding the extendedly dominated and dominated options) i.e. conventional management strategy. ^bCompared with the next most effective strategy (excluding the extendedly dominated and dominated options) i.e. etanercept.

ISSN: 1471-2474